Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Neurocrine Biosciences stock | 92.96

Own Neurocrine Biosciences stock in just a few minutes.


Fact checked

Neurocrine Biosciences, Inc is a biotechnology business based in the US. Neurocrine Biosciences shares (NBIX) are listed on the NASDAQ and all prices are listed in US Dollars. Neurocrine Biosciences employs 825 staff and has a trailing 12-month revenue of around USD$1 billion.

How to buy shares in Neurocrine Biosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Neurocrine Biosciences. Find the stock by name or ticker symbol: NBIX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Neurocrine Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$92.96, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Neurocrine Biosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Neurocrine Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Neurocrine Biosciences's share price?

Since the stock market crash in March caused by coronavirus, Neurocrine Biosciences's share price has had significant negative movement.

Its last market close was USD$92.96, which is 10.72% down on its pre-crash value of USD$104.12 and 28.86% up on the lowest point reached during the March crash when the shares fell as low as USD$72.14.

If you had bought USD$1,000 worth of Neurocrine Biosciences shares at the start of February 2020, those shares would have been worth USD$786.94 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$925.88.

Neurocrine Biosciences share price

Use our graph to track the performance of NBIX stocks over time.

Neurocrine Biosciences shares at a glance

Information last updated 2020-11-26.
Latest market close USD$92.96
52-week range USD$72.14 - USD$136.2618
50-day moving average USD$97.1075
200-day moving average USD$111.6256
Wall St. target price USD$126.43
PE ratio 91.7526
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.963

Buy Neurocrine Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Neurocrine Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Neurocrine Biosciences price performance over time

Historical closes compared with the close of $92.96 from 2020-11-16

1 week (2020-11-20) 4.45%
1 month (2020-10-30) -5.79%
3 months (2020-08-28) -18.68%
6 months (2020-05-29) -25.49%
1 year (2019-11-29) -20.28%
2 years (2018-11-29) 7.20%
3 years (2017-11-29) 35.91%
5 years (2015-11-27) 61.30%

Is Neurocrine Biosciences under- or over-valued?

Valuing Neurocrine Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neurocrine Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Neurocrine Biosciences's P/E ratio

Neurocrine Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 92x. In other words, Neurocrine Biosciences shares trade at around 92x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Neurocrine Biosciences's PEG ratio

Neurocrine Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.87. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Neurocrine Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Neurocrine Biosciences's EBITDA

Neurocrine Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$349.1 million.

The EBITDA is a measure of a Neurocrine Biosciences's overall financial performance and is widely used to measure a its profitability.

Neurocrine Biosciences financials

Revenue TTM USD$1 billion
Operating margin TTM 32.69%
Gross profit TTM USD$580.6 million
Return on assets TTM 15.87%
Return on equity TTM 13.55%
Profit margin 8.96%
Book value $8.611
Market capitalisation USD$8.9 billion

TTM: trailing 12 months

Shorting Neurocrine Biosciences shares

There are currently 5.1 million Neurocrine Biosciences shares held short by investors – that's known as Neurocrine Biosciences's "short interest". This figure is 1.8% up from 5.0 million last month.

There are a few different ways that this level of interest in shorting Neurocrine Biosciences shares can be evaluated.

Neurocrine Biosciences's "short interest ratio" (SIR)

Neurocrine Biosciences's "short interest ratio" (SIR) is the quantity of Neurocrine Biosciences shares currently shorted divided by the average quantity of Neurocrine Biosciences shares traded daily (recently around 993451.65048544). Neurocrine Biosciences's SIR currently stands at 5.15. In other words for every 100,000 Neurocrine Biosciences shares traded daily on the market, roughly 5150 shares are currently held short.

However Neurocrine Biosciences's short interest can also be evaluated against the total number of Neurocrine Biosciences shares, or, against the total number of tradable Neurocrine Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neurocrine Biosciences's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Neurocrine Biosciences shares in existence, roughly 50 shares are currently held short) or 0.0523% of the tradable shares (for every 100,000 tradable Neurocrine Biosciences shares, roughly 52 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Neurocrine Biosciences.

Find out more about how you can short Neurocrine Biosciences stock.

Neurocrine Biosciences share dividends

We're not expecting Neurocrine Biosciences to pay a dividend over the next 12 months.

Neurocrine Biosciences share price volatility

Over the last 12 months, Neurocrine Biosciences's shares have ranged in value from as little as $72.14 up to $136.2618. A popular way to gauge a stock's volatility is its "beta".

NBIX.US volatility(beta: 1.14)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurocrine Biosciences's is 1.1443. This would suggest that Neurocrine Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Neurocrine Biosciences overview

Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL ? Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site